GURU.Markets stock price, segment price, and overall market index valuation
The company's share price IN8bio Inc.
Shares of IN8bio, a biotech company developing cell therapy based on gamma-delta T cells, are a venture bet on a new approach to cancer treatment. Their price is highly volatile and driven by news of clinical trials.
Share prices of companies in the market segment - Cancer blood
IN8bio is an oncology company developing gamma-delta T-cell-based cell therapy for the treatment of blood cancers and solid tumors. We've categorized it as "Blood Cancer." The chart below shows how investors view this innovative but high-risk biotech sector.
Broad Market Index - GURU.Markets
IN8bio is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how IN8bio compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
INAB - Daily change in the company's share price IN8bio Inc.
IN8bio, Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures sensitivity to news about clinical trials of its cell therapy for blood cancer.
Daily change in the price of a set of shares in a market segment - Cancer blood
IN8bio develops cutting-edge cell therapies to combat cancer, operating in one of the most dynamic and risky segments of biotech. The chart below shows the average daily volatility in this sector. Compare it to INAB's stock price to assess how their movements align with overall industry sentiment.
Daily change in the price of a broad market stock, index - GURU.Markets
IN8bio is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization IN8bio Inc.
IN8bio, Inc.'s year-over-year performance is a story about developing a cell therapy based on gamma-delta T cells. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its approach could offer a new cancer treatment option that is safer and more effective than existing cell therapies.
Annual dynamics of market capitalization of the market segment - Cancer blood
IN8bio, Inc. is a clinical-stage biotech company developing gamma-delta T-cell-based cell therapy. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the significant risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
IN8bio, a cancer cell therapy company, is a shining example of a company whose market capitalization is determined by future breakthroughs. Its year-over-year performance relative to the market is a barometer of investor expectations for the success of its innovative treatments, which could revolutionize approaches to oncology and create enormous value, regardless of market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization IN8bio Inc.
IN8bio is an oncology company developing innovative cell therapy. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the efficacy of its unique gamma-delta T-cell technology are the main driver.
Monthly dynamics of market capitalization of the market segment - Cancer blood
IN8bio, Inc. is a clinical-stage biopharmaceutical company pioneering the development of gamma-delta T-cell therapy for cancer. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it's possible to assess how its unique approach, harnessing the innate tumor-killing properties of these cells, is progressing in trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
IN8bio is a biotech company developing cell therapies. Its shares don't follow the market, but rather move in leaps and bounds following the release of research data. The chart shows the monthly dynamics, which reflect investors' faith in its scientific platform rather than the state of the global economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization IN8bio Inc.
IN8bio is an oncology company developing cell therapy based on gamma-delta T cells. Its weekly stock price is a speculative bet on the success of this unique immunotherapy platform.
Weekly dynamics of market capitalization of the market segment - Cancer blood
IN8bio, Inc. is a biotech company specializing in cancer cell therapy. The chart helps separate the stock's unique reaction to clinical trial news from overall sector sentiment. Is the weekly price movement specific to IN8bio or is it an industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
IN8bio, Inc. is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
INAB - Market capitalization of the company IN8bio Inc.
The chart for IN8bio, Inc. shows a bet on a new type of cell therapy. The market cap of this company, which is developing gamma-delta T-cell-based therapy for cancer treatment, reflects investors' belief that this approach could be safer and more effective than existing methods.
INAB - Share of the company's market capitalization IN8bio Inc. within the market segment - Cancer blood
IN8bio is a biopharmaceutical company developing gamma-delta T-cell-based cell therapy for the treatment of blood cancers. Its market capitalization in this segment reflects the uniqueness of its approach, which may be safer than traditional CAR-T therapy. The company's market capitalization reflects the success of its clinical trials.
Market capitalization of the market segment - Cancer blood
IN8bio is a cell therapy company. How big is this arena? The chart below shows the pulse of the blood cancer treatment sector. Its high volatility reflects both the enormous hopes for a new generation of "living drugs" and the high risks associated with their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
The IN8bio chart shows how the market values cutting-edge cell therapy. The market cap of a company developing a gamma-delta T-cell-based cancer treatment is a venture bet on a new approach in immuno-oncology. It's a chart full of scientific risk and the promise of a breakthrough.
Book value capitalization of the company, segment and market as a whole
INAB - Book value capitalization of the company IN8bio Inc.
For IN8bio, a cell therapy company, book value is its tangible foundation: its gamma-delta T-cell laboratories, the rights to the DeltEx platform, and its financial reserves. The chart below shows how the company built this scientific and financial foundation to fight cancer.
INAB - Share of the company's book capitalization IN8bio Inc. within the market segment - Cancer blood
IN8bio, Inc. is a cell therapy company. Its main assets are its own (GMP) manufacturing facilities where gamma-delta T cells are grown and modified to fight cancer. This facility is the physical heart of its technology. The chart shows the share of this unique biotech infrastructure the company controls.
Market segment balance sheet capitalization - Cancer blood
IN8bio is a cell therapy company. Pharmaceuticals, as the chart shows, are capital-intensive. IN8bio is a prime example. Its business requires the construction of its own highly complex and expensive laboratories and factories to produce cell therapy products.
Book value of all companies included in the broad market index - GURU.Markets
IN8bio's assets are not drugs, but laboratories and a pilot plant for developing cell therapy based on a specific type of T-cell (gamma-delta) for cancer treatment. The book value reflects the material base for this unique approach in immuno-oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - IN8bio Inc.
IN8bio is a biotech company developing cell therapy based on gamma-delta T cells. Its value lies in this unique scientific platform. The chart shows how the market views its potential for cancer treatment.
Market to book capitalization ratio in a market segment - Cancer blood
IN8bio is a biotech company developing cell therapies for cancer treatment. Its valuation is based on its unique DeltEx platform. The chart shows how investors view its scientific approach and potential to fight cancer.
Market to book capitalization ratio for the market as a whole
IN8bio is a cancer cell therapy company. Its entire market value is based on the potential of its scientific platform. This chart illustrates how, in cutting-edge biotech, valuation reflects investors' belief in a future revolution in cancer treatment.
Debts of the company, segment and market as a whole
INAB - Company debts IN8bio Inc.
IN8bio is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. This is a cutting-edge and complex technology that requires significant investment. This chart shows how the company is raising significant funds to finance its unique and very expensive clinical trials and research.
Market segment debts - Cancer blood
IN8bio is a clinical-stage biotech company developing cell therapy based on gamma-delta T cells. Its financial structure is typical for biotech: no revenue and reliance on equity capital to fund R&D. This chart shows its cash reserves.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio IN8bio Inc.
IN8bio is a biopharmaceutical company working in cancer cell therapy. This chart shows its financial structure. For a company in the clinical trials stage, debt is a huge risk. All resources should be focused on research, not on interest payments.
Market segment debt to market segment book capitalization - Cancer blood
IN8bio is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. This is a novel and promising approach in immuno-oncology. The chart shows the overall debt burden in the sector, which helps understand how the company finances its cutting-edge, yet highly risky and expensive, research.
Debt to book value of all companies in the market
IN8bio, Inc. is a clinical-stage immuno-oncology company specializing in gamma-delta T cells. This is cutting-edge science. This chart, reflecting the debt of an established economy, emphasizes that IN8bio's funding is a venture bet on the future of medicine, not traditional lending, which requires stable cash flows.
P/E of the company, segment and market as a whole
P/E - IN8bio Inc.
For IN8bio, a company developing cell therapy for cancer, the P/E ratio is not applicable. The company is not profitable, and its valuation on this chart is arbitrary. It is a speculative bet that its unique treatment approach will prove safe and effective in clinical trials.
P/E of the market segment - Cancer blood
IN8bio is a clinical-stage biopharmaceutical company specializing in the development of gamma-delta T-cell therapy for cancer. This chart shows the average market valuation for the sector, helping to understand how the market views this innovative approach in immuno-oncology.
P/E of the market as a whole
IN8bio is a biotech company developing cell therapies for cancer. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. IN8bio's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company IN8bio Inc.
IN8bio is a clinical-stage biotech company developing gamma-delta T-cell-based cell therapy for the treatment of cancer. This chart reflects investor expectations for its innovative approach. The valuation is based on the potential to offer a new treatment method effective against solid tumors and blood cancers.
%20P%2FE%20IN8bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-IN8bio-Inc.&v=1772641057410 "Chart of the company's future (projected) P/E IN8bio Inc.")
Future (projected) P/E of the market segment - Cancer blood
IN8bio is a clinical-stage immuno-oncology company specializing in the development of gamma-delta T-cell-based therapies. Its valuation relative to other cell therapy companies reflects investors' appreciation of its unique approach. This is a bet that its technology will effectively fight cancer with fewer side effects.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772641057432 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
IN8bio is a biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. This is a new and promising approach in immuno-oncology. This chart shows the overall risk appetite of investors. For companies at the forefront of science like IN8bio, a positive market environment is critical to funding lengthy and expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641057437 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit IN8bio Inc.
IN8bio is a clinical-stage immuno-oncology company specializing in the development of gamma-delta T-cell-based therapies for the treatment of cancer. The financial performance shown here reflects the costs of clinical trials of this novel and promising cell therapy approach.
Profit of companies in the market segment - Cancer blood
IN8bio is an oncology company developing cell therapy based on gamma-delta T cells. This is another innovative approach. This chart reflects the financial state of the hematological oncology sector. It shows how saturated the cell therapy market is and whether there is room for new technologies with potentially improved safety profiles.
Overall market profit
IN8bio is a biopharmaceutical company specializing in cancer cell therapy. This is a cutting-edge but risky field. The company's value is determined solely by scientific data. The macroeconomic cycles visible in this chart are irrelevant to INAB compared to the results of clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company IN8bio Inc.
IN8bio is a biotech company developing cell therapies for cancer. Its future profit projections depend on the success of its clinical programs. This chart shows how analysts assess the potential of its unique approach to cancer treatment.
%20profit%20of%20the%20company%20IN8bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-IN8bio-Inc.&v=1772641057495 "Graph of future (projected) profit of the company IN8bio Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
IN8bio is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. This approach may be safer and more versatile than existing methods. This chart shows forecasts for the blood cancer sector, illustrating the hopes for scientific breakthroughs that could lead to new, more accessible cell therapies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772641057517 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
For IN8bio, a cancer cell therapy company, this chart is an indicator of the investment climate. Expectations of economic growth and investor appetite for risk are driving an influx of capital into biotech, which is necessary for long-term and expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641057524 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - IN8bio Inc.
IN8bio is a company developing cell therapies for cancer treatment. With no commercial products, its valuation, as shown in this chart, is based solely on investors' faith in its scientific developments.
P/S market segment - Cancer blood
IN8bio is a biopharmaceutical company focused on developing innovative gamma-delta T-cell-based cell therapy for the treatment of cancer. This chart shows the average valuation in the oncology sector. It reflects investor confidence in this new approach to cell therapy, which may be safer and more effective for solid tumors.
P/S of the market as a whole
IN8bio, Inc. is a clinical-stage immuno-oncology company developing gamma-delta T-cell-based therapy for the treatment of cancer. This is a novel approach to cell therapy. The company's valuation is based on the potential of this innovative platform. This chart helps assess how the market views cutting-edge scientific developments in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company IN8bio Inc.
IN8bio is an oncology company developing gamma-delta T-cell-based therapy. Its valuation is based on the future potential of this new cell therapy. The chart demonstrates investors' confidence that its approach will be effective and safer than existing cancer treatments.
%20P%2FS%20IN8bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-IN8bio-Inc.&v=1772641057544 "The graph of the company's future (projected) P/S IN8bio Inc.")
Future (projected) P/S of the market segment - Cancer blood
IN8bio is an immuno-oncology company developing gamma-delta T-cell-based cell therapy for the treatment of cancer, including brain tumors. This approach differs from traditional CAR-T therapy. This chart shows how investors view the potential of this new and risky technology.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772641057554 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
This chart shows general expectations for the cell therapy market. For IN8bio, a company developing gamma-delta T-cell-based therapy, this reflects the appetite for innovation. Market optimism is helping fund a new approach to cancer treatment that could be effective and have fewer side effects.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641057571 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales IN8bio Inc.
IN8bio is a clinical immuno-oncology company developing gamma-delta T-cell-based therapies for the treatment of cancer. This chart reflects grant revenue. Future revenue will depend on the success of clinical trials of this innovative cell therapy, which can attack tumors without the side effects associated with other treatments.
Sales of companies in the market segment - Cancer blood
IN8bio, Inc. is a clinical-stage immuno-oncology company specializing in gamma-delta T-cell therapy. This chart shows the growth of the blood cancer treatment market. This type of T-cell has unique properties, and IN8bio is a pioneer in using it to fight cancer, opening up new horizons.
Overall market sales
IN8bio, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for the treatment of blood cancers. Its development depends on successful research. The overall economic situation, shown in this chart, affects the availability of capital to finance innovative, but risky, approaches to cancer treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company IN8bio Inc.
IN8bio is an immuno-oncology company developing gamma-delta T-cell-based therapies for the treatment of cancer, including brain tumors. This approach represents a new direction in cell therapy. This timeline reflects analysts' expectations for the success of clinical trials of this innovative platform.
%20sales%20of%20the%20company%20IN8bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-IN8bio-Inc.&v=1772641057613 "Schedule of future (projected) sales of the company IN8bio Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
IN8bio is a biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. This chart shows expectations for the hematopoietic oncology sector. It illustrates the interest in new types of cell therapies that could overcome the limitations of existing approaches.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772641057615 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
IN8bio, Inc. is a clinical-stage immuno-oncology company specializing in the development of gamma-delta T-cell-based cell therapies. Its future depends on the success of its unique approach. The overall economic environment, reflected in this chart, impacts the availability of capital for funding cutting-edge but high-risk biotech platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641057615 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality IN8bio Inc.
IN8bio is a biotech company specializing in cancer cell therapy using gamma-delta T cells. This chart shows the company's financial performance at the clinical trial stage. Negative values represent investments in a unique approach that could be effective against difficult-to-treat tumors.
Market segment marginality - Cancer blood
IN8bio, Inc. is a biopharmaceutical company specializing in the development of gamma-delta T-cell therapy for cancer. For a company in the research stage, this chart serves as a benchmark. It shows the average profitability in the sector, illustrating the potential profitability should their cutting-edge treatments be successful and enter the market.
Market marginality as a whole
IN8bio is a clinical-stage biopharmaceutical company specializing in cell-based cancer therapy using gamma-delta T cells. This overall market profitability graph is irrelevant to the company. Its potential lies in creating a breakthrough technology. Success will be determined by clinical results and scientific advances.
Employees in the company, segment and market as a whole
Number of employees in the company IN8bio Inc.
IN8bio is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. This chart shows the scientific and clinical teams working on this cutting-edge technology. Their numbers reflect progress in clinical programs.
Share of the company's employees IN8bio Inc. within the market segment - Cancer blood
IN8bio, Inc. is a pioneer in developing gamma-delta T-cell-based therapies for cancer treatment. This chart shows the percentage of leading immunologists and cell engineers the company attracts in this unique and promising field. It reflects its concentration of rare scientific talent for the development of a new class of drugs.
Number of employees in the market segment - Cancer blood
IN8bio is a biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. This is a new and promising approach in immuno-oncology. This graph demonstrates the dynamic nature of science, where new cell types and mechanisms are constantly being discovered, forming the basis for the creation of breakthrough drugs.
Number of employees in the market as a whole
IN8bio, Inc. is a cell therapy company. Its focus on fighting blood cancers highlights the depth of specialization in modern oncology. This graph reflects the economics that can support such a diversity of scientific approaches, increasing the chances of finding effective treatments and creating unique scientific jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company IN8bio Inc. (INAB)
IN8bio is a biotech company developing gamma-delta T-cell therapy for cancer. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its unique scientific platform. The chart demonstrates the high future value the market is pricing into this cutting-edge science.
%20of%20the%20company%20IN8bio%20Inc.%20(INAB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-IN8bio-Inc.-INAB&v=1772641057659 "Chart of market capitalization per employee (in thousands of dollars) of the company IN8bio Inc. (INAB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
IN8bio is a biotech company working on cell therapy for blood cancer. The chart shows how investors view their scientific platform and team. In this competitive field, a high employee ratio may indicate that investors see a particular advantage in their approach.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772641057670 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
IN8bio, Inc. is a biopharmaceutical company developing cell therapies for cancer. This chart reflects the market's perceived value per employee, highlighting the company's high valuation of cutting-edge cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641057697 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company IN8bio Inc. (INAB)
IN8bio is a clinical-stage biotech company focused on cancer cell therapy. The company has no commercial products. This chart shows the net loss per employee, reflecting how much the company "burns" per scientist.
%20Chart%20IN8bio%20Inc.%20(INAB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-IN8bio-Inc.-INAB&v=1772641057722 "Company Profit Per Employee (in thousands of dollars) Chart IN8bio Inc. (INAB)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. Its value lies in its unique scientific platform. This graph will likely show negative earnings per employee, which is typical for companies that invest heavily in their scientific team and long-term research.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772641057728 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
IN8bio (INAB) is a clinical-stage biotech company developing Gamma-Delta T-cell therapy (a type of cell therapy) for the treatment of cancer (including glioblastoma). This is an R&D business. This chart shows the average profitability per employee across the market. For INAB (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641057730 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee IN8bio Inc. (INAB)
IN8bio is a clinical-stage immuno-oncology company working with gamma-delta T cells. This chart is a glimpse into the future, reflecting the enormous revenue potential if its unique cell therapy approach proves successful and is approved for cancer treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-IN8bio-Inc.-INAB&v=1772641057732 "Sales chart per company employee IN8bio Inc. (INAB)")
Sales per employee in the market segment - Cancer blood
IN8bio is a biotech company developing cell therapy (based on gamma-delta T cells) for cancer treatment. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of IN8bio's scientific team.
Sales per employee for the market as a whole
IN8bio is a clinical-stage biotech company developing cell therapy (gamma-delta T cells) for cancer treatment. The company has no commercial products or revenue, which is irrelevant. Their entire value lies in the potential of their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company IN8bio Inc. (INAB)
IN8bio is a biotech company developing cell therapy (gamma-delta T cells) for cancer treatment. This is an extremely complex and expensive technology. This chart shows the activity of the bears, who are betting that their approach will prove ineffective or too difficult to commercialize, and the company will run out of money.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-IN8bio-Inc.-INAB&v=1772641057759 "Short Shares Chart for the Company IN8bio Inc. (INAB)")
Shares shorted by market segment - Cancer blood
IN8bio, Inc. is an immuno-oncology company developing gamma-delta T-cell-based cell therapy for the treatment of cancer, including brain tumors. This chart reflects the total short position in the cell therapy sector. High values indicate general investor skepticism about the success of clinical trials of new, less-studied cell therapy approaches.
Shares shorted by the overall market
IN8bio (INAB) is a biotech company focused on cell therapy. It's one of the most advanced and speculative technologies. When this market fear indicator rises, investors aren't willing to wait 10 years. They're selling off profit-less "research projects" en masse, like INAB, to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator IN8bio Inc. (INAB)
IN8bio (INAB) is a biotech company focused on cell therapy (gamma-delta T cells) for the treatment of blood cancers and solid tumors. It is at the forefront of oncology. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) on positive data or "oversold" (below 30) due to capital dilution or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-IN8bio-Inc.-INAB&v=1772641057794 "RSI 14 indicator chart for the company's stock IN8bio Inc. (INAB)")
RSI 14 Market Segment - Cancer blood
IN8bio is a biopharmaceutical company at the forefront of cell therapy. It develops innovative cancer treatments (including blood cancers) using gamma-delta T cells. This chart shows the overall "temperature" in the volatile gene and cell therapy sector. It helps separate IN8bio's momentum from the general "hype" or "disappointment" in this complex field.
RSI 14 for the overall market
IN8bio (INAB) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INAB (IN8bio Inc.)
IN8bio is a biotech company specializing in gamma-delta T cells, a new type of cell therapy for cancer (leukemia, tumors). This chart shows the average target price. Analysts' forecasts are based on clinical data and the potential of this platform as an off-the-shelf treatment.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INAB-IN8bio-Inc.&v=1772641057819 "A chart showing analyst consensus forecasts for the expected stock price. INAB (IN8bio Inc.)")
The difference between the consensus estimate and the actual stock price INAB (IN8bio Inc.)
IN8bio is an immuno-oncology company, a pioneer in gamma-delta T-cell therapy. Their goal is to use this unique type of T-cell to treat blood cancers. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INAB-IN8bio-Inc.&v=1772641057821 "A chart showing the difference between the consensus forecast and the actual stock price. INAB (IN8bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
IN8bio is a biotech company developing cell therapy (gamma-delta T cells) that can attack cancer without being killed by chemotherapy. This chart shows the overall expectations for the hematopoietic oncology sector. It reflects whether experts believe this R&D platform can achieve breakthroughs.
Analysts' consensus forecast for the overall market share price
IN8bio (INAB) is a biopharmaceutical company working at the forefront of immuno-oncology. They are developing "super T cells" (gamma-delta T cells) to treat blood cancers. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough, but extremely expensive, cancer treatments.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index IN8bio Inc.
IN8bio is a gamma-delta biotech. They are pioneering the development of gamma-delta T cells—an alternative immune army (not CAR-T) that they are arming to attack blood cancer (leukemia). This chart is a clear indicator of faith in their R&D. It reflects their progress in clinical trials and the market's confidence in their unique immunological approach.
AKIMA Market Segment Index - Cancer blood
IN8bio (INAB) is a cell therapy company taking a different approach. They are developing CAR-T cells based on gamma-delta T cells (rather than alpha-beta cells), which they believe attack blood cancers and solid tumors more effectively and safely. This chart shows the average index for the segment, helping to assess how this unique platform compares to the average.
The AKIM Index for the overall market
IN8bio is a biotech company developing gamma-delta T-cell therapies for cancer treatment (leukemia, glioblastoma). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop important for funding this cell platform.
